# OnCo record ielsg-19 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ielsg-19/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ielsg-19", "NCT00210353" ;
  schema:name "IELSG-19"@en ;
  schema:alternateName "IELSG19"@en, "Chlorambucil versus rituximab versus both in MALT lymphoma"@en ;
  schema:description "The first randomised trial of first-line drug treatment for MALT lymphoma found that combining an old tablet with an antibody delayed relapse better than either alone, without anyone living longer."@en ;
  schema:url <https://onco.cc/trials/ielsg-19/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00210353>, <https://doi.org/10.1200/JCO.2016.70.6994> ;
  onco:status "mixed" ;
  onco:tag "lymphoma-evidence" ;
  onco:phase "3" ;
  schema:startDate "2003-01" ;
  onco:cancers <https://onco.cc/cancers/malt-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/rituximab/> ;
  onco:companies <https://onco.cc/companies/ielsg/> ;
  onco:terms <https://onco.cc/terms/watchful-waiting/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-trial-enrolment/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017/> .